A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer

Jerome Martin Laurence, Peter Duy Tran, Kavita Morarji, Guy D. Eslick, Vincent Wai To Lam, Charbel Sandroussi

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Introduction: This systematic review and meta-analysis aims to characterize the surgically important benefits and complications associated with the use of neoadjuvant chemoradiotherapy for the treatment of both resectable and initially unresectable pancreatic cancer. Studies were identified through a systematic literature search and analyzed by two independent reviewers. Survival, peri-operative complications, death rate, pancreatic fistula rate, and the incidence of involved surgical margins were analyzed and subject to meta-analysis. Methods: Nineteen studies, involving 2,148 patients were identified. Only cohort studies were included. Results: The meta-analysis found that patients with unresectable pancreatic cancer who underwent neoadjuvant chemoradiotherapy achieved similar survival outcomes to patients with resectable disease, even though only 40% were ultimately resected. Neoadjuvant chemoradiotherapy was not associated with a statistically significant increase in the rate of pancreatic fistula formation or total complications. Conclusion: Patients receiving neoadjuvant chemoradiotherapy were less likely to have a positive resection margin, although there was an increase in the risk of peri-operative death.

Original languageEnglish
Pages (from-to)2059-2069
Number of pages11
JournalJournal of Gastrointestinal Surgery
Volume15
Issue number11
DOIs
Publication statusPublished - 1 Nov 2011
Externally publishedYes

Keywords

  • Chemoradiotherapy
  • Meta-analysis
  • Neoadjuvant treatment
  • Pancreatic neoplasms
  • Systematic review

Fingerprint Dive into the research topics of 'A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this